BOSTON ( TheStreet) -- The best biotech CEO of 2012 is Leonard Schleifer of Regeneron Pharmaceuticals ( REGN - Get Report).

Schleifer was the top pick of TheStreet readers for his execution of one of the most successful new drug launches in history. Eylea was approved in November 2011 to treat a common cause of blindness. In just nine months, Eylea sales have already reached $562 million with an annual run rate close to $1 billion, well above the company's -- and investors' -- initial forecasts.

Well done, Len!

Schleifer wins the 2012 Best Biotech CEO Award with 37% of 1,121 votes cast. For his victory, Schleifer takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.

The runner-up this year was Onyx Pharmaceuticals' ( ONXX) Tony Coles with 28% of votes cast. With two new cancer drug approvals in 2012, Coles had a stellar year.

Right behind Coles in third place, just six votes short, was Chris Garabedian of Sarepta Therapeutics ( SRPT - Get Report). In fourth place: Gilead Sciences' ( GILD - Get Report) John Martin.

Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process.

-- Reported by Adam Feuerstein in Boston.